300 related articles for article (PubMed ID: 31280266)
21. USP8: a novel therapeutic target for Cushing's disease.
Jian F; Cao Y; Bian L; Sun Q
Endocrine; 2015 Nov; 50(2):292-6. PubMed ID: 26162929
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel
Uzilov AV; Cheesman KC; Fink MY; Newman LC; Pandya C; Lalazar Y; Hefti M; Fowkes M; Deikus G; Lau CY; Moe AS; Kinoshita Y; Kasai Y; Zweig M; Gupta A; Starcevic D; Mahajan M; Schadt EE; Post KD; Donovan MJ; Sebra R; Chen R; Geer EB
Cold Spring Harb Mol Case Stud; 2017 May; 3(3):a001602. PubMed ID: 28487882
[TBL] [Abstract][Full Text] [Related]
23. Genetics of Cushing's disease.
Albani A; Theodoropoulou M; Reincke M
Clin Endocrinol (Oxf); 2018 Jan; 88(1):3-12. PubMed ID: 28850717
[TBL] [Abstract][Full Text] [Related]
24. Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas.
Ronchi CL; Peverelli E; Herterich S; Weigand I; Mantovani G; Schwarzmayr T; Sbiera S; Allolio B; Honegger J; Appenzeller S; Lania AG; Reincke M; Calebiro D; Spada A; Buchfelder M; Flitsch J; Strom TM; Fassnacht M
Eur J Endocrinol; 2016 Mar; 174(3):363-72. PubMed ID: 26701869
[TBL] [Abstract][Full Text] [Related]
25. USP8, USP48, and BRAF mutations differ in their genotype-phenotype correlation in Asian Indian patients with Cushing's disease.
Abraham AP; Pai R; Beno DL; Chacko G; Asha HS; Rajaratnam S; Kapoor N; Thomas N; Chacko AG
Endocrine; 2022 Feb; 75(2):549-559. PubMed ID: 34664215
[TBL] [Abstract][Full Text] [Related]
26. Molecular basis of ubiquitin-specific protease 8 autoinhibition by the WW-like domain.
Kakihara K; Asamizu K; Moritsugu K; Kubo M; Kitaguchi T; Endo A; Kidera A; Ikeguchi M; Kato A; Komada M; Fukushima T
Commun Biol; 2021 Nov; 4(1):1272. PubMed ID: 34750505
[TBL] [Abstract][Full Text] [Related]
27. Cushing's disease: towards precision medicine.
Kaiser UB
Cell Res; 2015 Jun; 25(6):649-50. PubMed ID: 25930709
[TBL] [Abstract][Full Text] [Related]
28. Responsiveness to DDAVP in Cushing's disease is associated with USP8 mutations through enhancing AVPR1B promoter activity.
Shichi H; Fukuoka H; Kanzawa M; Yamamoto M; Yamamoto N; Suzuki M; Urai S; Matsumoto R; Kanie K; Fujita Y; Bando H; Iguchi G; Inoshita N; Yamada S; Takahashi Y; Ogawa W
Pituitary; 2022 Jun; 25(3):496-507. PubMed ID: 35451730
[TBL] [Abstract][Full Text] [Related]
29. Case Report: Consecutive Adrenal Cushing's Syndrome and Cushing's Disease in a Patient With Somatic
Detomas M; Altieri B; Schlötelburg W; Appenzeller S; Schlaffer S; Coras R; Schirbel A; Wild V; Kroiss M; Sbiera S; Fassnacht M; Deutschbein T
Front Endocrinol (Lausanne); 2021; 12():731579. PubMed ID: 34489873
[TBL] [Abstract][Full Text] [Related]
30. Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease.
Araki T; Tone Y; Yamamoto M; Kameda H; Ben-Shlomo A; Yamada S; Takeshita A; Yamamoto M; Kawakami Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3346-e3363. PubMed ID: 34061962
[TBL] [Abstract][Full Text] [Related]
31. Gene expression profiling in human corticotroph tumours reveals distinct, neuroendocrine profiles.
Cassarino MF; Ambrogio AG; Cassarino A; Terreni MR; Gentilini D; Sesta A; Cavagnini F; Losa M; Pecori Giraldi F
J Neuroendocrinol; 2018 Sep; 30(9):e12628. PubMed ID: 29920815
[TBL] [Abstract][Full Text] [Related]
32. Transcription Factor ASCL1 Acts as a Novel Potential Therapeutic Target for the Treatment of the Cushing's Disease.
Chen Z; Jia Q; Zhao Z; Zhang Q; Chen Y; Qiao N; Ye Z; Ji C; Zhang Y; He W; Shi C; Cai Y; Yao B; Han R; Wang Y; Shou X; Shen M; Cao X; Zhou X; Cheng H; Zhu J; Hu Y; Zhang Z; Ye H; Li Y; Li S; Wang Y; Ma Z; Ni T; Zhao Y
J Clin Endocrinol Metab; 2022 Jul; 107(8):2296-2306. PubMed ID: 35521682
[TBL] [Abstract][Full Text] [Related]
33. Somatic
Pérez-Rivas LG; Theodoropoulou M; Puar TH; Fazel J; Stieg MR; Ferraù F; Assié G; Gadelha MR; Deutschbein T; Fragoso MC; Kusters B; Saeger W; Honegger J; Buchfelder M; Korbonits M; Bertherat J; Stalla GK; Hermus AR; Beuschlein F; Reincke M
Eur J Endocrinol; 2018 Jan; 178(1):57-63. PubMed ID: 28982703
[TBL] [Abstract][Full Text] [Related]
34. Germline USP8 Mutation Associated With Pediatric Cushing Disease and Other Clinical Features: A New Syndrome.
Cohen M; Persky R; Stegemann R; Hernández-Ramírez LC; Zeltser D; Lodish MB; Chen A; Keil MF; Tatsi C; Faucz FR; Buchner DA; Stratakis CA; Tiosano D
J Clin Endocrinol Metab; 2019 Oct; 104(10):4676-4682. PubMed ID: 31162547
[TBL] [Abstract][Full Text] [Related]
35. Ubiquitin-specific Protease 8 Gene Expression in Sporadic Pituitary Adenomas.
Hatipoglu E; Gunaldi O; Erkan B; Avcikurt A; Mert M; Niyazoglu M
Neuro Endocrinol Lett; 2022 Jun; 43(2):129-133. PubMed ID: 35981231
[TBL] [Abstract][Full Text] [Related]
36. Genetic Basis of ACTH-Secreting Adenomas.
Locantore P; Paragliola RM; Cera G; Novizio R; Maggio E; Ramunno V; Corsello A; Corsello SM
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743266
[TBL] [Abstract][Full Text] [Related]
37. USP8 mutation in Cushing's disease.
Huang C; Shi Y; Zhao Y
Oncotarget; 2015 Jul; 6(21):18240-1. PubMed ID: 26285834
[No Abstract] [Full Text] [Related]
38. Genetics: New mutations in Cushing disease identified.
Greenhill C
Nat Rev Endocrinol; 2015 Mar; 11(3):131. PubMed ID: 25534197
[No Abstract] [Full Text] [Related]
39. Ubiquitin-specific protease 8 (USP8/UBPy): a prototypic multidomain deubiquitinating enzyme with pleiotropic functions.
Dufner A; Knobeloch KP
Biochem Soc Trans; 2019 Dec; 47(6):1867-1879. PubMed ID: 31845722
[TBL] [Abstract][Full Text] [Related]
40. Silibinin, an HSP90 Inhibitor, on Human ACTH-Secreting Adenomas.
Pecori Giraldi F; Cassarino MF; Sesta A; Lasio G; Losa M
Neuroendocrinology; 2023; 113(6):606-614. PubMed ID: 36791678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
